Raymond James Biotech Innovation Symposium: Korro Bio CEO Ram Aiyer discussed how the company has chosen new RNA editing programs to move forward with this year
After experiencing a setback last year with Korro's LNP delivered alpha-1 antitrypsin deficiency program, he describes learnings from that experience and how Korro has new momentum with a galNAc delivered approach targeting urea cycle disorders, hepatic encephalophy, and new alpha-1 program. The company recently closed a $85 private placement.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.